Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia

Š. Šestáková, C. Šálek, D. Kundrát, E. Cerovská, J. Vydra, I. Ježíšková, A. Folta, J. Mayer, P. Cetkovský, H. Remešová

. 2024 ; 16 (1) : 17. [pub] 20240122

Language English Country Germany

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24007541

BACKGROUND: Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with prognosis. However, studies integrating these numerous and potentially prognostically relevant DNA methylation changes are lacking. Therefore, we aimed for an overall evaluation of these epigenetic aberrations to provide a comprehensive NGS-based approach of DNA methylation assessment for AML prognostication. RESULTS: We designed a sequencing panel targeting 239 regions (approx. 573 kb of total size) described in the literature as having a prognostic impact or being associated with AML pathogenesis. Diagnostic whole-blood DNA samples of adult AML patients divided into a training (n = 128) and a testing cohort (n = 50) were examined. The libraries were prepared using SeqCap Epi Enrichments System (Roche) and sequenced on MiSeq instrument (Illumina). Altogether, 1935 CpGs affecting the survival (p < 0.05) were revealed in the training cohort. A summarizing value MethScore was then calculated from these significant CpGs. Patients with lower MethScore had markedly longer overall survival (OS) and event-free survival (EFS) than those with higher MethScore (p < 0.001). The predictive ability of MethScore was verified on the independent testing cohort for OS (p = 0.01). Moreover, the proof-of-principle validation was performed using the TCGA dataset. CONCLUSIONS: We showed that comprehensive NGS-based approach of DNA methylation assessment revealed a robust epigenetic signature relevant to AML outcome. We called this signature MethScore and showed it might serve as a strong prognostic marker able to refine survival probability of AML patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007541
003      
CZ-PrNML
005      
20240423160039.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13148-024-01625-x $2 doi
035    __
$a (PubMed)38254139
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Šestáková, Šárka $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia / $c Š. Šestáková, C. Šálek, D. Kundrát, E. Cerovská, J. Vydra, I. Ježíšková, A. Folta, J. Mayer, P. Cetkovský, H. Remešová
520    9_
$a BACKGROUND: Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with prognosis. However, studies integrating these numerous and potentially prognostically relevant DNA methylation changes are lacking. Therefore, we aimed for an overall evaluation of these epigenetic aberrations to provide a comprehensive NGS-based approach of DNA methylation assessment for AML prognostication. RESULTS: We designed a sequencing panel targeting 239 regions (approx. 573 kb of total size) described in the literature as having a prognostic impact or being associated with AML pathogenesis. Diagnostic whole-blood DNA samples of adult AML patients divided into a training (n = 128) and a testing cohort (n = 50) were examined. The libraries were prepared using SeqCap Epi Enrichments System (Roche) and sequenced on MiSeq instrument (Illumina). Altogether, 1935 CpGs affecting the survival (p < 0.05) were revealed in the training cohort. A summarizing value MethScore was then calculated from these significant CpGs. Patients with lower MethScore had markedly longer overall survival (OS) and event-free survival (EFS) than those with higher MethScore (p < 0.001). The predictive ability of MethScore was verified on the independent testing cohort for OS (p = 0.01). Moreover, the proof-of-principle validation was performed using the TCGA dataset. CONCLUSIONS: We showed that comprehensive NGS-based approach of DNA methylation assessment revealed a robust epigenetic signature relevant to AML outcome. We called this signature MethScore and showed it might serve as a strong prognostic marker able to refine survival probability of AML patients.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a metylace DNA $7 D019175
650    12
$a akutní myeloidní leukemie $x diagnóza $x genetika $7 D015470
650    _2
$a prognóza $7 D011379
650    _2
$a epigenomika $7 D057890
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šálek, Cyril $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kundrát, Dávid $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic
700    1_
$a Cerovská, Ela $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Ježíšková, Ivana $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine, Brno, Czech Republic
700    1_
$a Folta, Adam $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine, Brno, Czech Republic
700    1_
$a Cetkovský, Petr $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Remešová, Hana $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 00, Prague, Czech Republic. hana.remesova@uhkt.cz
773    0_
$w MED00186202 $t Clinical epigenetics $x 1868-7083 $g Roč. 16, č. 1 (2024), s. 17
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38254139 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160036 $b ABA008
999    __
$a ok $b bmc $g 2081504 $s 1217308
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 16 $c 1 $d 17 $e 20240122 $i 1868-7083 $m Clinical epigenetics $n Clin Epigenetics $x MED00186202
LZP    __
$a Pubmed-20240412
Back

Find record

Citation metrics

Archiving options